Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

European Urology

Volumn 45, Issue 4, 2004, Pages 420-429

  Haab, F ^a   Stewart, L ^b   Dwyer, P ^c  

^a HÔPITAL TENON   (France)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

Darifenacin; Efficacy; Overactive bladder; Safety; Tolerability

Indexed keywords

DARIFENACIN; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; BENZOFURAN DERIVATIVE; PYRROLIDINE DERIVATIVE;

ADULT; AGED; AROUSAL; ATRIOVENTRICULAR BLOCK; BLADDER CAPACITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CLOTHING; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIAPER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DYSPEPSIA; EDEMA; FEMALE; FLATULENCE; GASTRITIS; HEADACHE; HEART DISEASE; HUMAN; INFORMATION PROCESSING; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; REVIEW; SAMPLE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TONGUE DISEASE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY FREQUENCY; URINARY TRACT DISEASE; URINARY URGENCY; URTICARIA; VISUAL IMPAIRMENT; XEROSTOMIA; BLADDER DISEASE; MIDDLE AGED; URINE INCONTINENCE;

ADULT; AGED; AGED, 80 AND OVER; BENZOFURANS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRROLIDINES; URINARY BLADDER DISEASES; URINARY INCONTINENCE;

EID: 1642276168     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.01.008     Document Type: Review

References (36)

1. Abrams P., Kelleher C.J., Kerr L.A., Rogers R.G. Overactive bladder significantly affects quality of life. Am. J. Manag. Care. 6:2000;S580-S590.
2. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 87:2001;760-766.
3. Milsom I., Stewart W., Thuroff J. The prevalence of overactive bladder. Am. J. Manag. Care. 6(Suppl 11):2000;S565-S573.
4. Ricci J.A., Baggish J.S., Hunt T.L., Stewart W.F., Wein A., Herzog A.R. et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin. Ther. 23:2001;1245-1259.
5. Wyndaele J.J. The overactive bladder. BJU Int. 88:2001;135-140.
6. Chess-Williams R. Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton. Autacoid. Pharmacol. 22:2002;133-145.
7. 3 muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol. 136:2002;641-643.
8. 3 receptor selectivity. Eur. Urol. Supplements. 1(4):2002;23-28.
9. Gupta S., Sathyan G., Mori T. New perspectives on the overactive bladder: pharmacokinetics and bioavailability. Urology. 60(Suppl 5A):2002;78-81.
10. 1 muscarinic agonists as potential disease-modifying agents in Alzheimer's disease. Rationale and perspectives. Ann. NY Acad. Sci. 920:2000;315-320.
11. 3 receptors regulate exocrine secretion by mucous acini. Am. J. Physiol. 271:1996;C1963-C1972.
12. 4 receptor subtypes using receptor knockout mice. Life Sci. 68:2001;2473-2479.
13. Gil D.W., Krauss H.A., Bogardus A.M., WoldeMussie E. Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest. Ophthalmol. Vis. Sci. 38:1997;1434-1442.
14. Choppin A., Eglen R.M. Pharmacological characterization of muscarinic receptors in dog isolated ciliary and urinary bladder smooth muscle. Br. J. Pharmacol. 132:2001;835-842.
15. Kelleher C.J., Cardozo L.D., Khullar V., Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. 104:1997;988-993.
16. Lawrence M., Guay D.R., Benson S.R., Anderson M.J. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy. 20:2000;470-475.
17. Amarenco G., Ismael S.S., Even-Schneider A., Raibaut P., Demaille-Wlodyka S., Parratte B.et al. Urodynamic effect of acute transcutaneous posterior tibial nerve stimulation in overactive bladder. J. Urol. 169:2003;2210-2215.
18. Wallis R.M., Napier C.M. Muscarinic antagonists in development for disorders of smooth muscle function. Life Sci. 64:1999;395-401.
19. Newgreen D.T., Anderson C.W.P., Carter A.J., Naylor A.M. Darifenacin - a novel bladder-selective agent for the treatment of urge incontinence. Neurourol. Urodyn. 14:1995;555-557. [Abstract 96].
20. Quinn P., Goka J., Richardson H. Assessment of an electronic daily diary in patients with overactive bladder. Br. J. Urol. Int. 91:2003;647-652.
21. Chapple C.R., Yamanishi T., Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology. 60(5 Suppl 1):2002;82-88.
22. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A. Tolterodine Study Group Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology. 57:2001;414-421.
23. Diokno A.C., Appell R.A., Sand P.K., Dmochowski R.R., Gburek B.M., Klimberg I.W., Kell S.H. OPERA Study Group Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. 78:2003;687-695.
24. Anderson R.U., Mobley D., Blank B., Saltzstein D., Susset J., Brown J.S. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence, OROS Oxybutynin Study Group. J. Urol. 161:1999;1809-1812.
25. Gleason D.M., Susset J., White C., Munoz D.R., Sand P.K. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology. 54:1999;420-423.
26. Versi E., Appell R., Mobley D., Patton W., Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet. Gynecol. 95:2000;718-721.
27. FDA Review: Ditropan XL needs longer trial to support superiority claim for dry mouth. Drug Development profiles. Pharmaceutical Approvals Monthly 1999;4:26-30.
28. Cardozo L, Prescott K, Serdarevic D, Skillern L. Can medication prolong warning time? Presented at the International Continence Society, 33rd Annual Meeting, Florence, Italy, 5-9 October 2003 [Abstract 74].
29. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J. Am. Geriatr. Soc. 46:1998;8-13.
30. Layton D., Pearce G.L., Shakir S.A. Safety profile of tolterodine as used in general practice in England: results of prescription-event monitoring. Drug Saf. 24:2001;703-713.
31. Womack K.B., Heilman K.M. Tolterodine and memory: dry but forgetful. Arch. Neurol. 60:2003;771-773.
32. Larsson G., Hallen B., Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology. 53:1999;990-998.
33. Rentzhog L., Stanton S.L., Cardozo L., Nelson E., Fall M., Abrams P. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br. J. Urol. 81:1998;42-48.
34. 3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers. Eur. Urol. Suppl. 3(2):2004;131. [Abstract 513].
35. Data on file. Novartis Pharmaceuticals. Study 224.
36. Data on file. Novartis Pharmaceuticals. Study 1041.